| Quarter | Revenue | Gross Profit | Op. Income |
|---|---|---|---|
| Q1 23 | $11.3B | $6.5B | $2.5B |
| Q2 23 | $11.2B | $6.1B | $1.9B |
| Q3 23 | $11.0B | $6.2B | $2.1B |
| Q4 23 | $11.5B | $6.5B | $2.0B |
| Q1 24 | $11.9B | $6.6B | $1.5B |
| Q2 24 | $12.2B | $6.8B | $2.6B |
| Q3 24 | $11.9B | $6.6B | $2.3B |
| Q4 24 | $12.3B | $7.4B | $2.5B |
| Q1 25 | $11.2B | $7.3B | $3.5B |
| Q2 25 | $12.3B | $8.1B | $4.1B |
| Q3 25 | $12.2B | $8.8B | $3.6B |
| Q4 25 | $12.5B | $8.4B | $1.4B |
| Quarter | P/S | P/E |
|---|---|---|
| Q1 23 | 2.7x | 16.9x |
| Q2 23 | 2.7x | 15.5x |
| Q3 23 | 2.8x | 14.9x |
| Q4 23 | 2.8x | 15.4x |
| Q1 24 | 2.7x | — |
| Q2 24 | 2.7x | — |
| Q3 24 | 2.6x | — |
| Q4 24 | 2.6x | — |
| Q1 25 | 2.6x | 22.8x |
| Q2 25 | 2.6x | 24.5x |
| Q3 25 | 2.6x | 20.5x |
| Q4 25 | 2.6x | 17.5x |
| Quarter | Operating CF | Free CF |
|---|---|---|
| Q1 23 | $3.0B | $2.7B |
| Q2 23 | $1.9B | $1.6B |
| Q3 23 | $4.8B | $4.4B |
| Q4 23 | $4.3B | $3.9B |
| Q1 24 | $2.8B | $2.5B |
| Q2 24 | $2.3B | $2.1B |
| Q3 24 | $5.6B | $5.3B |
| Q4 24 | $4.4B | $4.1B |
| Q1 25 | $2.0B | $1.7B |
| Q2 25 | $3.9B | $3.6B |
| Q3 25 | $6.3B | $6.0B |
| Q4 25 | $2.0B | $1.6B |
| Quarter | CapEx |
|---|---|
| Q1 23 | $278M |
| Q2 23 | $259M |
| Q3 23 | $342M |
| Q4 23 | $330M |
| Q1 24 | $284M |
| Q2 24 | $262M |
| Q3 24 | $324M |
| Q4 24 | $378M |
| Q1 25 | $260M |
| Q2 25 | $361M |
| Q3 25 | $320M |
| Q4 25 | $370M |
| Quarter | Revenue Growth | OpEx Growth |
|---|---|---|
| Q1 23 | -2.7% | -0.6% |
| Q2 23 | -5.6% | +0.9% |
| Q3 23 | -2.2% | -1.4% |
| Q4 23 | +0.6% | -1.7% |
| Q1 24 | +4.7% | +16.3% |
| Q2 24 | +8.7% | +3.6% |
| Q3 24 | +8.4% | +8.4% |
| Q4 24 | +7.5% | +3.0% |
| Q1 25 | -5.6% | -25.7% |
| Q2 25 | +0.6% | -15.2% |
| Q3 25 | +2.8% | -10.6% |
| Q4 25 | +1.3% | +13.0% |
| Quarter | SBC ($) | % of Revenue |
|---|---|---|
| Q1 23 | $122M | 1.1% |
| Q2 23 | $137M | 1.2% |
| Q3 23 | $132M | 1.2% |
| Q4 23 | $127M | 1.1% |
| Q1 24 | $133M | 1.1% |
| Q2 24 | $125M | 1.0% |
| Q3 24 | $129M | 1.1% |
| Q4 24 | $120M | 1.0% |
| Q1 25 | $144M | 1.3% |
| Q2 25 | $137M | 1.1% |
| Q3 25 | $139M | 1.1% |
| Q4 25 | $133M | 1.1% |
| Quarter | R&D | G&A | S&M | SG&A |
|---|---|---|---|---|
| Q1 23 | $2.3B | — | — | $1.8B |
| Q2 23 | $2.3B | — | — | $1.9B |
| Q3 23 | $2.2B | — | — | $1.9B |
| Q4 23 | $2.5B | $664M | $1.4B | — |
| Q1 24 | $2.7B | — | $2.4B | — |
| Q2 24 | $2.3B | — | — | $1.9B |
| Q3 24 | $2.4B | — | $2.0B | — |
| Q4 24 | $2.8B | $352M | $1.5B | — |
| Q1 25 | $2.2B | — | $1.6B | — |
| Q2 25 | $2.3B | — | — | $1.7B |
| Q3 25 | $2.5B | — | — | $1.8B |
| Q4 25 | $2.6B | $2.2B | — | — |
| Quarter | Abecma | Abraxane | Breyanzi | Camzyos | Eliquis | Mature Products And All Other | Opdivo | Opdualag | Orencia | Pomalyst/Imnovid | Reblozyl | Revlimid | Sotyktu | Sprycel | Yervoy | Zeposia | Krazati | Other Growth Brands | Other Legacy Brands | Cobenfy | Opdivo Ovantig |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 23 | $147M | $239M | $71M | $29M | $3.4B | $467M | $2.2B | $117M | $764M | $832M | $206M | $1.8B | $16M | $429M | $508M | $78M | — | — | — | — | — |
| Q2 23 | $132M | $258M | $100M | $46M | $3.2B | $472M | $2.1B | $154M | $927M | $847M | $234M | $1.5B | $25M | $458M | $585M | $100M | — | — | — | — | — |
| Q3 23 | $93M | $260M | $92M | $68M | $2.7B | $476M | $2.3B | $166M | $925M | $872M | $248M | $1.4B | $66M | $517M | $579M | $123M | — | — | — | — | — |
| Q4 23 | $100M | $247M | $101M | $88M | $2.9B | — | $2.4B | $190M | $985M | $890M | $320M | $1.4B | $63M | $526M | $566M | $133M | — | — | — | — | — |
| Q1 24 | $82M | $217M | $107M | $84M | $3.7B | — | $2.1B | $206M | $798M | $865M | $354M | $1.7B | $44M | $374M | $583M | $110M | $21M | $319M | $228M | — | — |
| Q2 24 | $95M | $231M | $153M | $139M | $3.4B | — | $2.4B | $235M | $948M | $959M | $425M | $1.4B | $53M | $424M | $630M | $151M | $32M | $341M | $222M | — | — |
| Q3 24 | $124M | $253M | $224M | $156M | $3.0B | — | $2.4B | $233M | $936M | $898M | $447M | $1.4B | $66M | $290M | $642M | $147M | $34M | $433M | $225M | — | — |
| Q4 24 | $105M | $174M | $263M | $223M | $3.2B | — | $2.5B | $254M | $1.0B | $823M | $547M | $1.3B | $83M | $198M | $675M | $158M | $39M | $512M | $250M | — | — |
| Q1 25 | $103M | $105M | $263M | $159M | $3.6B | — | $2.3B | $252M | $770M | $658M | $478M | $936M | $55M | $175M | $624M | $107M | $48M | $403M | $199M | $27M | $9M |
| Q2 25 | $87M | $105M | $344M | $260M | $3.7B | — | $2.6B | $284M | $963M | $708M | $568M | $838M | $70M | $120M | $728M | $150M | $48M | $470M | $223M | $35M | $30M |
| Q3 25 | $137M | $74M | $359M | $296M | $3.7B | — | $2.5B | $299M | $964M | $675M | $615M | $575M | $80M | $119M | $739M | $161M | $53M | $514M | $177M | $43M | $67M |
| Q4 25 | $100M | $84M | $392M | $353M | $3.5B | — | $2.7B | $350M | $1.0B | $692M | $666M | $602M | $86M | $79M | $809M | $159M | $56M | $537M | $199M | $50M | $132M |
| Quarter | Other Region | Rest Of World | United States |
|---|---|---|---|
| Q1 23 | $155M | $3.1B | $8.0B |
| Q2 23 | $175M | $3.2B | $7.9B |
| Q3 23 | $185M | $3.2B | $7.6B |
| Q4 23 | $184M | $3.3B | $8.0B |
| Q1 24 | $199M | $3.2B | $8.5B |
| Q2 24 | $176M | $3.2B | $8.8B |
| Q3 24 | $271M | $3.4B | $8.2B |
| Q4 24 | $350M | $3.4B | $8.6B |
| Q1 25 | $218M | $3.1B | $7.9B |
| Q2 25 | $270M | $3.5B | $8.5B |
| Quarter | Cash | Short-term Investments | Total |
|---|---|---|---|
| Q1 23 | $9.0B | $274M | $9.3B |
| Q2 23 | $8.4B | $358M | $8.7B |
| Q3 23 | $7.5B | $171M | $7.7B |
| Q4 23 | $11.5B | $816M | $12.3B |
| Q1 24 | $9.3B | $340M | $9.7B |
| Q2 24 | $6.3B | $360M | $6.7B |
| Q3 24 | $7.9B | $204M | $8.1B |
| Q4 24 | $10.3B | $513M | $10.9B |
| Q1 25 | $10.9B | $907M | $11.8B |
| Q2 25 | $12.6B | $1.0B | $13.6B |
| Q3 25 | $15.7B | $776M | $16.5B |
| Q4 25 | $10.2B | $464M | $10.7B |
| Quarter | Shares (Diluted) | QoQ Change |
|---|---|---|
| Q1 23 | 2.11B | -0.5% |
| Q2 23 | 2.10B | -0.5% |
| Q3 23 | 2.06B | -1.8% |
| Q4 23 | 2.03B | -1.5% |
| Q1 24 | 2.02B | -0.5% |
| Q2 24 | 2.03B | +0.3% |
| Q3 24 | 2.03B | +0.1% |
| Q4 24 | 2.04B | +0.3% |
| Q1 25 | 2.04B | +0.0% |
| Q2 25 | 2.04B | +0.0% |
| Q3 25 | 2.04B | -0.0% |
| Q4 25 | 2.04B | +0.1% |
| Year | Revenue/Employee | Employees |
|---|---|---|
| FY 14 | $2M | 9K |
| FY 15 | $2M | 9K |
| FY 16 | $777K | 25K |
| FY 17 | $877K | 24K |
| FY 18 | $968K | 23K |
| FY 19 | $872K | 30K |
| FY 20 | $1M | 30K |
| FY 21 | $1M | 32K |
| FY 22 | $1M | 34K |
| FY 23 | $1M | 34K |
| FY 24 | $1M | 34K |
| FY 25 | $1M | 33K |